Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Staccato Apomorphine (AZ-009) in Parkinson's Disease OFF Episodes
NCT05979415Phase 2Terminated
- Sponsor
- Alexza Pharmaceuticals Inc
- Start
- Sep 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of apomorphine in Parkinson's disease (PD), sponsored by Alexza Pharmaceuticals Inc. Started Sep 2023; status: terminated.
02
Drugs
apomorphine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05979415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05979415.